We proudly announce that one of our start-ups, ONCOHUB/MIRIO has been selected to be the winner of the Unicancer Prize in the ‘care pathway’ category.
This prize is the single and most recognized prize for oncology innovation in France, rewarding the most innovative initiatives in the field of healthcare, research and organizations.
Particularly, it rewards:
- The enhancement of quality and security of care
- The participation to the economical well-being and organizational efficiency of all the French Comprehensive Cancer Centers (FCCC)
- The patient benefit brought, in relation to individualized and personalized medicine and with an emphasis on respecting transparency and patients’ expectations
• A dedicated corner for WeHealth at the ESC Congress in Munich, on August 25
The congress of the European Society of Cardiology is the largest medical congress in Europe with more than 30,000 active participants !
Thanks to a great booth design and a huge commitment of the whole team, we had a huge visibility both internally and externally during the whole congress.
We were able to present to the visitors our first partnerships and our ambition: Work in open innovation with start-ups to find new e-health solutions that improve care for patients and everyday life for healthcare professionals.
• A considerable success for our first partnerships
Cardioskin®, HomeHeart®, Mobiosense, and Betterise have successfully raised the interests of many doctors.
– CardioSkin®, when a t-shirt can monitor your heart
Cardioskin, ready to market, is a CE marked and 510k FDA US Clearance noninvasive medical device which allows ECG home monitoring and ambulatory diagnosis from a few days to several weeks. It is a simple system composed of 15 leads embedded in an innovative textile connected to an acquisition module that records an ECG signal. This module does an analog-digital conversion and sends the signal wirelessly to the cloud where the data are stored in a secure way but easily accessible to the treating physician who can make a more accurate and timely diagnosis without bringing the patient to the hospital.
Cardioskin ensures flexibility during the whole duration of the monitoring period, and a better patient acceptability.
– Homeheart, when a drop a blood can predict heart failure
CardioRenal and WeHealth by Servier have formed a partnership to develop HomeHeart® (early stage of development). It’s a unique tele-medicine device capable of detecting early signs of heart failure with a simple drop of blood. It aims at reducing rehospitalizations for patients suffering from heart failure.
– Mobiosense and Betterise
Even though they are still in development phase, these two cardiology and diabetes products have aroused the interest and many opportunities emerged for future developments or business.
We are thrilled to see how WeHealth has conveyed the image of innovation and patient‐centricity thanks to the display of innovative solutions, a lot of meetings and appointments, interviews with journalists or even the presence on social media.
What is Cardioskin ? How could it helps doctors spot risk of stoke?
A T-shirt that constantly monitors the heart’s activity and detects abnormalities could help protect people against stroke — and may even help diagnose the cause of fainting.
The high-tech shirt, called Cardioskin, has electrodes stitched into the cotton fabric which carry out round-the-clock checks on the heart’s electrical activity.
These then connect to a tiny chip in the garment which wirelessly beams the results to an app on the patient’s smartphone.
The app is able to share the data with a cardiologist, who can assess it.
On Thursday 22nd of March, WeHealth by Servier will be hosting its regular innovation meetup, based on the topic “AI and Big Data for better cancer treatment”
In 2017, new cancer cases was estimated at 3.7 million in China. Precision Oncology has become a promising field in cancer treatment for its ability to discern which patients would benefit the most from a particular treatment.
Using AI and Big Data, precision medicine makes analyzing and identifying specific biomarkers and treatment targets for diseases become possible based on personal genomics, proteomics, and metabolomics information.
In 2015, a national precision medicine strategy committee, which involved 19 experts, was set up. It also plans to invest RMB 60 billion on precision medicine between 2015 and 2030.
WeHealth will be present at the 4th Hello Tomorrow Global Summit on October 26-27 at Le Centquatre in Paris. Hello Tomorrow is a nonprofit organization present in 45 countries that is on a mission is to promote breakthrough technologies by connecting the most promising deep-tech entrepreneurs with investors and industrialists keen to provide support. Since 2014, Hello Tomorrow has organized an annual Hello Tomorrow Global Summit, which brings together the best deep-tech startups, influencers, industrialists, and investors.
Every year Hello Tomorrow identifies over 3000 projects in ten or more fields involving various technologies. This substantive groundwork highlights the broad trends of interest to startups, such as artificial intelligence and blockchains.
Hello Tomorrow is committed to defining scenarios of possible futures to enable us to choose which of them we wish to build.
David Guez, the Director of WeHealth, will be a member of the jury of the international startup challenge in the category healthcare. He will also take part in the Ask Them Anything round table on the future of healthcare, which will be moderated by Ludovic Sinet (Residence Creatis) and will bring together three healthcare pioneers: Joy Wolfram (Mayo Clinic), Laura Deming (The Longevity Fund), and Geoffrey Siwo (University of Notre Dame).
The Hello Tomorrow Global Summit is the ideal event for immersion in scientific innovation. If you are able to come, we will be delighted to welcome you to our stand!